Takeda Pharmaceutical Company Stock News

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after organ transplant. The infection is caused by

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVTENCITY (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofo

Wave Life Sciences Ltd. found using ticker (WVE) have now 7 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 17 and 6 with a mean TP of 9.86. Given that the stocks previous close was at 4.28 this would imply there is a potential upside of 130.4%. The 50 day moving average now sits at 4.9 and the 200 moving average now moves to 6.58. The company has a market cap of $254m. Find out more information at: /> [stock_market_widget type="chart" symbol="WVE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Gastroparesis Market report considers the latest upgrades while assessing the development of leading market players. This global market report is comprehensive and opens a door of worldwide market for the products. The report gives helpful insights which assist while launching

The Japanese life sciences company Takeda Pharmaceutical Company Limited is investing more than 100 million euros in a new building in Seestadt, Vienna. Read about the massive investment and see a picture of what it is supposed to look like upon completion.

Screening for stocks with market capitalizations exceeding $10 billion and price-book ratios below 1.5 could help value investors to discover more opportunities among U.S.-listed equities. Thus, value

Takeda Pharmaceutical Company Limited (OTCMKTS:TKPYY)s share price hit a new 52-week low during trading on Monday . The company traded as low as $14.39 and last traded at $14.41, with a volume of 1887085 shares traded. The stock had previously closed at $14.42. The firm has a 50 day simple moving average of $15.29 and []

Takeda Pharmaceutical Company Limited (NYSE:TAK) price closed lower on Tuesday, November 16, dropping -2.08% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The global Antidiabetics market will grow at a CAGR of 5.78% from 2021 to 2027. The antidiabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 690,000 shares of Takeda Pharmaceutical Co.

Complete study of the global Antiulcerant Drugs market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the

Takeda owns a very large portfolio of major drugs and an even larger drug pipeline: the present and the future look secured. The stock has never been so cheap: that's why a share repurchase program wa

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript